StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.67−1.15 (-9.73%)

Close on Nov 17, 2026Market cap $8.51BP/E –Yield –

Summit Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Summit Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $568.74M, up 63.2% year over year. For fiscal 2025 it was $537.67M, up 256.6% from the year before. The highest annual figure on record is $537.67M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$537.67M+256.6%
FY2024Dec 31, 2024$150.78M+153.5%
FY2023Dec 31, 2023$59.47M+14.4%
FY2022Dec 31, 2022$52.00M-39.1%
FY2021Dec 31, 2021$85.35M+64.1%
FY2019Jan 31, 2019$52.00M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$157.73M-24.2%
Q1 FY2026CQ1 2026Mar 31, 2026$132.62M+158.7%
Q4 FY2025CQ4 2025Dec 31, 2025$147.29M+186.7%
Q3 FY2025CQ3 2025Sep 30, 2025$131.10M+247.5%
Q2 FY2025CQ2 2025Jun 30, 2025$208.02M+575.4%
Q1 FY2025CQ1 2025Mar 31, 2025$51.27M+66.1%
Q4 FY2024CQ4 2024Dec 31, 2024$51.38M+107.1%
Q3 FY2024CQ3 2024Sep 30, 2024$37.72M+146.2%
Q2 FY2024CQ2 2024Jun 30, 2024$30.80M+225.9%
Q1 FY2024CQ1 2024Mar 31, 2024$30.87M+212.4%
Q4 FY2023CQ4 2023Dec 31, 2023$24.81M+360.7%
Q3 FY2023CQ3 2023Sep 30, 2023$15.32M-10.1%
Q2 FY2023CQ2 2023Jun 30, 2023$9.45M+4.9%
Q1 FY2023CQ1 2023Mar 31, 2023$9.88M-51.9%
Q4 FY2022CQ4 2022Dec 31, 2022$5.39M-76.7%
Q3 FY2022CQ3 2022Sep 30, 2022$17.05M-14.5%
Q2 FY2022CQ2 2022Jun 30, 2022$9.01M-62.3%
Q1 FY2022CQ1 2022Mar 31, 2022$20.56M+11.8%
Q4 FY2021CQ4 2021Dec 31, 2021$23.11M–
Q3 FY2021CQ3 2021Sep 30, 2021$19.94M–
Q2 FY2021CQ2 2021Jun 30, 2021$23.92M–
Q1 FY2021CQ1 2021Mar 31, 2021$18.38M–

More Summit Therapeutics figures

See a number that looks wrong?